Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

Annals of Oncology

Volumn 19, Issue 9, 2008, Pages 1605-1612

  Zucali, P A ^a   Ruiz, M G ^b   Giovannetti, E ^b   Destro, A ^a,c   Varella Garcia, M ^d   Floor, K ^b   Ceresoli, G L ^a   Rodriguez, J A ^b   Garassino, I ^a   Comoglio, P ^e   Roncalli, M ^a,c   Santoro, A ^a   Giaccone, G ^b,f  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^e UNIVERSITY OF TURIN   (Italy)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Activated cMET; Gefitinib resistance; Multitarget therapy; NSCLC

Indexed keywords

CMET TYROSINE KINASE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; TYROSINE KINASE RECEPTOR; UVOMORULIN;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; BIOPSY, NEEDLE; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 50849141873     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn240     Document Type: Article

References (26)

1. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: E73.
2. Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-792.
3. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol 2006; 11: 190-198.
4. Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: E17.
5. Giaccone G, Gallegos Ruiz M, Le Chevalier T et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: A phase II study. Clin Cancer Res 2006; 12: 6049-6055.
6. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-2326.
7. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin Cancer Res 2003; 9: 4340-4346.
8. Qin B, Ariyama H, Baba E et al. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol 2006; 58: 577-584.
9. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
10. Witta SE, Gemmill RM, Hirsch FR et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66: 944-950.
11. Yauch RL, Januario T, Eberhard DA et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005; 11: 8686-8698.
12. Natali PG, Prat M, Nicotra MR et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 1996; 69: 212-217.
13. Olivero M, Rizzo M, Madeddu R et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996; 74: 1862-1868.
14. Maulik G, Kijima T, Ma PC et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002; 8: 620-627.
15. Ma PC Jagadeeswaran, R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479-1488.
16. Mazzone M, Comoglio PM. The Met pathway: Master switch and drug target in cancer progression. FASEB J 2006; 20: 1611-1621.
17. Siegfried JM, Weissfeld LA, Luketich JD et al. The clinical significance of hepatocyte growth factor for non-small cell lung cancer, Ann Thorac Surg 1998; 66: 1915-1918.
18. Petrelli A, Circosta P, Granziero L et al. Antibody-induced ectodomain shedding mediates HGF receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 2006; 103: 5090-5095.
19. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
20. Therasse P. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
21. Meier R, Alessi DR, Cron P et al. Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase Bbeta. J Biol Chem 1997; 272: 30491-30497.
22. Cappuzzo F, Magrini E, Ceresoli GL et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96: 1133-1141.
23. Janmaat ML, Rodriguez JA, Gallegos-Ruiz M et al. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells. Int J Cancer 2006; 118: 209-214.
24. Prat M, Crepaldi T, Pennacchietti S et al. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998; 111: 237-247.
25. Chou TC, Motzer RJ, Tong Y, Bosl GJ. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design. J Natl Cancer Inst 1994; 86: 1517-1524.
26. Lutterbach B, Zeng Q, Davis LJ et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007; 67: 2081-2088.